ASCO 2017: What should be Duration of Adjuvant Oxaliplatin-based Therapy for Stage III Colon Cancer?

Speaker: Thierry Andre

Thierry Andre discusses the results from the IDEA collaboration, a prospective pooled analysis of six phase III trials aimed at demonstrating the optimal duration (3 vs 6 months) of adjuvant oxaliplatin-based therapy in patients with stage III colon cancer.

Thierry Andre discusses the results from the IDEA collaboration, a prospective pooled analysis of six phase III trials aimed at demonstrating the optimal duration (3 vs 6 months) of adjuvant oxaliplatin-based therapy in patients with stage III colon cancer.

Abstract as referenced in the ASCO 2017 programme:
LBA1: Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.